Takeda Pharmaceutical Files Routine 6-K Disclosure
Ticker: TKPHF · Form: 6-K · Filed: Mar 3, 2025 · CIK: 1395064
| Field | Detail |
|---|---|
| Company | Takeda Pharmaceutical Co Ltd (TKPHF) |
| Form Type | 6-K |
| Filed Date | Mar 3, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: routine-filing, foreign-private-issuer
TL;DR
Takeda filed a 6-K on 3/3/25, just a routine update, no big news.
AI Summary
Takeda Pharmaceutical Company Limited filed a Form 6-K on March 3, 2025, reporting as a foreign private issuer. The filing does not contain specific financial figures or operational updates but serves as a routine disclosure for the month of March 2025. Takeda is registered with the SEC under file number 001-38757 and is headquartered in Tokyo, Japan.
Why It Matters
This filing indicates Takeda is adhering to its reporting obligations as a foreign private issuer with the SEC, which is standard practice for international companies listed in the US.
Risk Assessment
Risk Level: low — This is a standard, routine filing with no new material financial or operational information that would typically impact risk.
Key Players & Entities
- TAKEDA PHARMACEUTICAL CO LTD (company) — Filer
- 0001395064-25-000032 (filing_id) — Accession Number
- 001-38757 (company_id) — SEC File Number
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, used to furnish information that the registrant may be required to disclose or make public in its home country.
When was this Form 6-K filed?
This Form 6-K was filed on March 3, 2025.
What period does this Form 6-K cover?
This Form 6-K is for the month of March 2025.
Is Takeda Pharmaceutical Company Limited required to file Form 20-F or 40-F?
Takeda Pharmaceutical Company Limited indicated it files annual reports under cover of Form 20-F.
What is Takeda's principal executive office address?
Takeda's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo 103-8668, Japan.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 3, 2025 regarding TAKEDA PHARMACEUTICAL CO LTD (TKPHF).